Literature DB >> 30673974

Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics.

Roberto Minutolo1, Luca De Nicola2, Ciro Gallo3, Paolo Chiodini3, Michele Provenzano2, Giuseppe Conte2, Carlo Garofalo2, Silvio Borrelli2.   

Abstract

BACKGROUND: The Systolic Blood Pressure Intervention Trial-CKD substudy (SPRINT-CKD) has suggested a lower blood pressure (BP) target in CKD patients. However, it is questionable whether the SPRINT-CKD results may be generalized to CKD patients under nephrology care.
METHODS: To compare SPRINT-CKD cohort versus referred CKD patients in terms of patients' risk profile and outcomes, we pooled four prospective cohorts of consecutive CKD patients referred to 40 Italian renal clinics. We implemented the same inclusion/exclusion criteria adopted in SPRINT and same endpoints: (1) a composite of fatal and non-fatal cardiovascular (CV) events (2) all-cause mortality and (3) ESRD (composite of chronic dialysis, transplantation or 50% eGFR decline). Findings were compared with those attained in the control arm of SPRINT-CKD trial that mirrored standard BP management in clinical practice.
RESULTS: Out of 2847 patients referred to renal clinics, only 20.1% (n = 571) were identified as eligible for SPRINT-CKD. Age (72 ± 9 years), gender (42.2% female) and systolic BP (142 ± 10 mmHg) did not differ from the SPRINT-CKD while referred patients had a worse risk profile at baseline: larger prevalence of prior CV disease (25.7% versus 19.5%), higher Framingham risk score (31.9 ± 14.6% versus 27.2 ± 24.7%) and lower GFR (38 ± 11 versus 48 ± 10 mL/min/1.73 m2). During 4.0 years of follow-up, 86 CV events (50 fatal), 78 all-cause death and 59 ESRD occurred with annual incidence rates higher than those observed in the SPRINT-CKD control group (CV events 4.18 vs 3.19; all-cause death 3.64 vs 2.21; ESRD 2.80 vs 0.41%/year).
CONCLUSIONS: The SPRINT-CKD cohort is poorly representative of the CKD population under nephrology care, thus suggesting that conclusions may not apply to patients referred to nephrologist.

Entities:  

Keywords:  Cardiovascular risk; Chronic kidney disease; Hypertension; SPRINT trial

Year:  2019        PMID: 30673974     DOI: 10.1007/s40620-019-00588-0

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  35 in total

1.  Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention.

Authors:  L De Nicola; R Minutolo; P Chiodini; C Zoccali; P Castellino; C Donadio; M Strippoli; F Casino; M Giannattasio; F Petrarulo; M Virgilio; E Laraia; B R Di Iorio; V Savica; G Conte
Journal:  Kidney Int       Date:  2006-02       Impact factor: 10.612

2.  Effect of general population mortality on the north-south mortality gradient in patients on replacement therapy in Europe.

Authors:  P C W van Dijk; A H Zwinderman; F W Dekker; S Schön; V S Stel; P Finne; K J Jager
Journal:  Kidney Int       Date:  2006-11-08       Impact factor: 10.612

3.  Timing of onset of CKD-related metabolic complications.

Authors:  Olivier Moranne; Marc Froissart; Jerome Rossert; Cedric Gauci; Jean-Jacques Boffa; Jean Philippe Haymann; Mona Ben M'rad; Christian Jacquot; Pascal Houillier; Benedicte Stengel; Bruno Fouqueray
Journal:  J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 10.121

4.  Prognosis of CKD patients receiving outpatient nephrology care in Italy.

Authors:  Luca De Nicola; Paolo Chiodini; Carmine Zoccali; Silvio Borrelli; Bruno Cianciaruso; Biagio Di Iorio; Domenico Santoro; Vincenzo Giancaspro; Cataldo Abaterusso; Ciro Gallo; Giuseppe Conte; Roberto Minutolo
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 8.237

5.  Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation.

Authors:  Hicham Skali; Hajime Uno; Andrew S Levey; Lesley A Inker; Marc A Pfeffer; Scott D Solomon
Journal:  Am Heart J       Date:  2011-08-09       Impact factor: 4.749

6.  Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease.

Authors:  Roberto Minutolo; Rajiv Agarwal; Silvio Borrelli; Paolo Chiodini; Vincenzo Bellizzi; Felice Nappi; Bruno Cianciaruso; Pasquale Zamboli; Giuseppe Conte; Francis B Gabbai; Luca De Nicola
Journal:  Arch Intern Med       Date:  2011-06-27

7.  Albuminuria and racial disparities in the risk for ESRD.

Authors:  William M McClellan; David G Warnock; Suzanne Judd; Paul Muntner; Reshma Kewalramani; Mary Cushman; Leslie A McClure; Britt B Newsome; George Howard
Journal:  J Am Soc Nephrol       Date:  2011-08-25       Impact factor: 10.121

8.  Factors associated with kidney disease progression and mortality in a referred CKD population.

Authors:  Richard A Hoefield; Philip A Kalra; Patricia Baker; Beverley Lane; John P New; Donal J O'Donoghue; Robert N Foley; Rachel J Middleton
Journal:  Am J Kidney Dis       Date:  2010-08-08       Impact factor: 8.860

9.  Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.

Authors:  Roberto Minutolo; Francesco Locatelli; Maurizio Gallieni; Renzo Bonofiglio; Giorgio Fuiano; Lamberto Oldrizzi; Giuseppe Conte; Luca De Nicola; Filippo Mangione; Pasquale Esposito; Antonio Dal Canton
Journal:  Nephrol Dial Transplant       Date:  2013-10-21       Impact factor: 5.992

10.  Association of race and sex with risk of incident acute coronary heart disease events.

Authors:  Monika M Safford; Todd M Brown; Paul M Muntner; Raegan W Durant; Stephen Glasser; Jewell H Halanych; James M Shikany; Ronald J Prineas; Tandaw Samdarshi; Vera A Bittner; Cora E Lewis; Christopher Gamboa; Mary Cushman; Virginia Howard; George Howard
Journal:  JAMA       Date:  2012-11-07       Impact factor: 56.272

View more
  1 in total

1.  Clinical comparison between trial participants and potentially eligible patients using electronic health record data: A generalizability assessment method.

Authors:  James R Rogers; George Hripcsak; Ying Kuen Cheung; Chunhua Weng
Journal:  J Biomed Inform       Date:  2021-05-25       Impact factor: 8.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.